MedTrace Logo

Study of Telbivudine in Chronic Hepatitis B

NCT00970216 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 160

Last updated 2016-02-29

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the safety, tolerability and antiviral efficacy of telbivudine by maintained suppression of hepatitis B virus (HBV) DNA (\<=300 copies/ml or 60IU/ml, undetectable by current polymerase chain reaction (PCR) - based assays) in HBeAg positive/negative patients at physician's general practice.

Conditions

Interventions

DRUG

Telbivudine

Post-marketing observation for chronic hepatitis B patients receiving Telbivudine treatment

Sponsors & Collaborators

  • Chang Gung Memorial Hospital

    lead OTHER

Principal Investigators

  • Chau-ting Yeh, MD,PhD · Chang Gung Memorial Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2016-01-31
Completion
2016-01-31

Countries

  • Taiwan

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00970216 on ClinicalTrials.gov